Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma
Clinical trial NCT05683704 · UNKNOWN
Trial details
- NCT number
- NCT05683704
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-01
- Primary completion
- 2024-05-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.